Royalty Pharma Declares Third Quarter 2025 Dividend
Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend payment for Q3 2025. The company will distribute a dividend of $0.22 per Class A ordinary share. The dividend is scheduled to be paid on September 10, 2025, to shareholders who are registered as of the record date on August 15, 2025.
Royalty Pharma (Nasdaq: RPRX) ha annunciato il pagamento del dividendo trimestrale per il terzo trimestre del 2025. La società distribuirà un dividendo di 0,22 $ per azione ordinaria di Classe A. Il dividendo sarà pagato il 10 settembre 2025 agli azionisti registrati alla data di riferimento del 15 agosto 2025.
Royalty Pharma (Nasdaq: RPRX) ha anunciado el pago de su dividendo trimestral para el tercer trimestre de 2025. La compañía distribuirá un dividendo de 0,22 $ por acción ordinaria Clase A. El dividendo se pagará el 10 de septiembre de 2025 a los accionistas registrados a la fecha de corte del 15 de agosto de 2025.
Royalty Pharma (나스닥: RPRX)는 2025년 3분기 분기 배당금을 발표했습니다. 회사는 클래스 A 보통주 1주당 0.22달러의 배당금을 지급할 예정입니다. 배당금은 2025년 9월 10일에 지급되며, 2025년 8월 15일 기준일에 등록된 주주에게 지급됩니다.
Royalty Pharma (Nasdaq : RPRX) a annoncé le versement de son dividende trimestriel pour le troisième trimestre 2025. La société distribuera un dividende de 0,22 $ par action ordinaire de classe A. Le dividende sera versé le 10 septembre 2025 aux actionnaires inscrits à la date de référence du 15 août 2025.
Royalty Pharma (Nasdaq: RPRX) hat die Quartalsdividende für das dritte Quartal 2025 angekündigt. Das Unternehmen wird eine Dividende von 0,22 $ pro Class A Stammaktie ausschütten. Die Dividende wird am 10. September 2025 an die Aktionäre ausgezahlt, die zum Stichtag 15. August 2025 eingetragen sind.
- Consistent dividend payment demonstrates commitment to shareholder returns
- None.
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of
The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What is Royalty Pharma's (RPRX) dividend amount for Q3 2025?
When is the dividend payment date for Royalty Pharma's Q3 2025 dividend?
What is the record date for Royalty Pharma's Q3 2025 dividend?
What type of shares are eligible for Royalty Pharma's Q3 2025 dividend?
